<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24418" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Loperamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sahi</surname>
            <given-names>Nidhi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Rosalee</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Santos</surname>
            <given-names>Cynthia</given-names>
          </name>
          <aff>Rutgers New Jersey Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nidhi Sahi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rosalee Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cynthia Santos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24418.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Loperamide is an FDA-approved synthetic phenylpiperidine opioid with high lipophilicity and is a medication used to treat various forms of diarrhea. Recognized and approved by the FDA, loperamide is an effective intervention for conditions such as traveler's diarrhea, irritable bowel syndrome associated with chronic diarrhea, and acute nonspecific diarrhea in patients older than 2. Loperamide is also indicated for conditions requiring reducing ileostomy output to manage diverse gastrointestinal challenges. However, this medication requires careful consideration due to its potential for misuse, with reports indicating a concerning increase in morbidity and mortality associated with high doses. This activity explores loperamide's indications, contraindications, activities, and adverse events, focusing on the essential elements crucial for members of an interprofessional healthcare team involved in managing patients facing toxicity and its related conditions.</p>
        <p>As the misuse of loperamide gains prevalence, this activity&#x000a0;discusses the complexities surrounding its abuse, providing crucial insights for healthcare professionals. Understanding the risks and nuances associated with loperamide is paramount, ensuring a comprehensive approach to patient care that addresses potential complications and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate patient candidates for loperamide therapy based on medical history and the presence of diarrhea.</p></list-item><list-item><p>Screen patients for potential contraindications, drug interactions, and risk factors for loperamide misuse to ensure safe and appropriate use.</p></list-item><list-item><p>Apply evidence-based guidelines and best practices for using loperamide in different clinical scenarios, such as chemotherapy-induced diarrhea or non-medical use.</p></list-item><list-item><p>Communicate the risks and benefits of loperamide therapy to patients, ensuring they understand the proper use and potential adverse effects.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24418&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24418">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24418.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Loperamide is an over-the-counter oral antidiarrheal agent&#x000a0;synthesized in 1969, first used medically in 1976, and became available without a prescription in 1988.<xref ref-type="bibr" rid="article-24418.r1">[1]</xref>&#x000a0;Initially, the Federal Drug Administration (FDA) categorized it as a Schedule V drug due to its opioid-like misuse potential.<xref ref-type="bibr" rid="article-24418.r2">[2]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Currently, loperamide&#x000a0;has been&#x000a0;approved by the FDA to treat various forms of diarrhea and has also been used off-label to treat the adverse effects of chemotherapy resulting in diarrhea. In recent years, there has been an increased interest in the non-medical use of loperamide, ranging from self-management of opioid withdrawal symptoms to a means to induce euphoria (ie, getting high). Recently, a new syndrome termed loperamide-induced cardiotoxicity has come to light.<xref ref-type="bibr" rid="article-24418.r3">[3]</xref>&#x000a0;Patients can present with different forms of potentially life-threatening dysrhythmias when using loperamide in toxic doses.</p>
        <p><bold>Medical Use: </bold>The FDA has approved loperamide for treating various forms of diarrhea, including traveler&#x02019;s diarrhea, irritable bowel syndrome associated with chronic diarrhea, and acute nonspecific diarrhea in patients&#x000a0;2 and older,&#x000a0;in addition to the&#x000a0;indication for reducing ileostomy output.<xref ref-type="bibr" rid="article-24418.r4">[4]</xref><xref ref-type="bibr" rid="article-24418.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The off-label uses include the management of chemotherapy-related diarrhea.&#x000a0;According to ASCO (American Society of Clinical Oncology) guidelines, loperamide may be used for diarrhea associated with&#x000a0;immune checkpoint inhibitor (ICPi) therapy; however, infection and colitis must be ruled out before&#x000a0;initiating loperamide.<xref ref-type="bibr" rid="article-24418.r6">[6]</xref></p>
        <p><bold>Illicit Drug Use and Self-Medication Use:</bold> In recent years, there has been a noticeable incline in the use and abuse of loperamide as a means of self-management of opioid withdrawal and an inexpensive method to induce euphoria, ie, to achieve a euphoric state. Vakkalanka et al found a 91% increase in reported loperamide exposures, including&#x000a0;8 deaths, from 2010 to 2015 across Poison Control Centers in the United States.<xref ref-type="bibr" rid="article-24418.r7">[7]</xref>&#x000a0;</p>
        <p>Individuals have used loperamide as a means to self-medicate to decrease the withdrawal&#x000a0;adverse effects of opioid dependence or slow the tapering process. Recently, high-dose loperamide has shown promise for such use.<xref ref-type="bibr" rid="article-24418.r8">[8]</xref></p>
      </sec>
      <sec id="article-24418.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Loperamide is a lipophilic synthetic phenylpiperidine opioid&#x000a0;and a &#x003bc;-receptor agonist.<xref ref-type="bibr" rid="article-24418.r4">[4]</xref><xref ref-type="bibr" rid="article-24418.r9">[9]</xref>&#x000a0;At therapeutic doses, loperamide acts on the &#x003bc;-opioid receptors directly on the circular and longitudinal intestinal muscles to decrease transition time, inhibit peristalsis electrolyte loss, and increase rectal tone.&#x000a0;However, because loperamide is a substrate for P-glycoprotein at higher doses, P-glycoprotein is&#x000a0;inhibited, allowing loperamide to cross the blood-brain barrier and act on the central nervous system, producing central opioid effects and toxicity.<xref ref-type="bibr" rid="article-24418.r10">[10]</xref></p>
        <p>Loperamide was also found to inhibit both the Na<sup>+</sup> gated cardiac channels, which prolongs the QRS complex, and the hERG channel,&#x000a0;which increases the QTc interval.<xref ref-type="bibr" rid="article-24418.r11">[11]</xref>&#x000a0;QRS and QTc prolongation can cause ventricular dysrhythmias, monomorphic and polymorphic ventricular tachycardia, torsade de pointes, ventricular fibrillation, Brugada syndrome, cardiac arrest, and death.</p>
        <p>
<bold>(a) Pharmacokinetics</bold>
</p>
        <p><bold>(i) Absorption:</bold> The peak plasma time is 4&#x000a0;to 5 hours, with a half-life of 7&#x000a0;to 19 hours.<xref ref-type="bibr" rid="article-24418.r12">[12]</xref> Loperamide has a low bioavailability (&#x0003c;1%) due to the first-pass metabolism.</p>
        <p><bold>(ii) Distribution:</bold> Loperamide has high protein binding and a large volume of distribution.</p>
        <p><bold>(iii) Metabolism:</bold> Loperamide is extracted in the GI tract and metabolized in the liver by the cytochrome P450 pathway.&#x000a0;The drug is metabolized in the liver via CYP2C8 and CYP3A4 to desmethyl-loperamide.<xref ref-type="bibr" rid="article-24418.r3">[3]</xref>&#x000a0;This pathway allows for decreased gastrointestinal uptake and, thus, enhanced elimination through bile excretion. At recommended doses, almost no active loperamide is&#x000a0;present in the systemic circulation.</p>
        <p><bold>(iv) Elimination:</bold>&#x000a0;The elimination half-life of loperamide varies between 9.1 to 14.4 hours.&#x000a0;The excretion of loperamide and its metabolites&#x000a0;is predominantly through feces.</p>
      </sec>
      <sec id="article-24418.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Loperamide is available in different formulations, most commonly as tablets, capsules, and orodispersible tablets that melt on the tongue. Loperamide is available as 2 mg tablets, capsules, and oral solutions of 1 mg/7.5 mL and 2 mg/15 mL strengths. The oral solution should be shaken well before being administered to the patient. Consider administering loperamide with plenty of fluids to prevent dehydration. A combination of loperamide 2 mg and simethicone 125 mg is also available for the symptomatic relief of diarrhea plus bloating.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The usual initial recommended dose for acute diarrhea, such as traveler&#x02019;s diarrhea, is a 4 mg starting dose, followed by 2 mg after each unformed stool. The total dose is not to exceed 8 mg daily for over-the-counter use and 16 mg daily for prescription use. For chronic use, the suggested dose is 2 mg twice daily. Consider administering loperamide 30 minutes before food&#x000a0;4 times daily for patients with chemotherapy-induced&#x000a0;diarrhea to slow colic reflex.</p>
        <p>According to the Infectious Disease Society of America, clinicians can use loperamide as adjuvant therapy with close monitoring and concomitant antibiotics in patients with suspected or known dysentery.<xref ref-type="bibr" rid="article-24418.r13">[13]</xref>&#x000a0;Loperamide is usually avoided in patients with <italic toggle="yes">C difficile</italic>&#x000a0;infection; however, some experts approve using close monitoring and concomitant antibiotics if the patient has significant fluid losses and no contraindications (ileus/colonic distention).<xref ref-type="bibr" rid="article-24418.r14">[14]</xref></p>
        <p><bold>Chemotherapy-induced diarrhea (off-label use):</bold> Initially administer 4 mg, followed by 2 mg every&#x000a0;2 to&#x000a0;4 hours or after each loose stool. For diarrhea persisting for more than 24 hours, administer 2 mg every&#x000a0;2 hours (or 4 mg every&#x000a0;4 hours). Continue until 12 hours have passed without a loose bowel movement. Experts consider recommending alternative therapy for diarrhea persisting more than 48 hours, and doses of more than 16 mg per day might not provide benefit.<xref ref-type="bibr" rid="article-24418.r15">[15]</xref>&#x000a0;Loperamide is used to prevent diarrhea caused by neratinib and irinotecan.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold><bold>Hepatic impairment:&#x000a0;</bold></bold>No dose adjustment of loperamide for&#x000a0;hepatic impairment is provided in the product labeling; use caution in patients with liver impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>According to manufacturer labeling, no dose adjustment is required in patients with mild to severe renal impairment. In addition, since it is highly protein-bound, no dose adjustment is needed for dialysis.&#x000a0;</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>There are no adverse effects observed in animal studies. There is a lack of data on loperamide use in pregnant women, and the information is conflicting.<xref ref-type="bibr" rid="article-24418.r16">[16]</xref>&#x000a0;For managing acute diarrhea in pregnancy, some experts recommend only oral rehydration and dietary modifications. Loperamide is also recommended in the lowest possible amount if the patient&#x02019;s symptoms are disabling.<xref ref-type="bibr" rid="article-24418.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Loperamide may be excreted into breast milk. The study on loperamide oxide (prodrug of loperamide) was conducted in breastfeeding women and found variable concentrations of loperamide and loperamide oxide in breast milk.<xref ref-type="bibr" rid="article-24418.r18">[18]</xref>&#x000a0;Manufacturers recommend against breastfeeding. Furthermore, loperamide is contraindicated in children younger than&#x000a0;2.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>According to the Infectious Disease Society of America, loperamide is not recommended to manage infectious diarrhea in pediatric patients.<xref ref-type="bibr" rid="article-24418.r19">[19]</xref>&#x000a0;Use a minimum effective dose for the possible shortest duration. Loperamide is not recommended for children younger than 2. Consider calculating the dose based on weight:</p>
        <list list-type="bullet">
          <list-item>
            <p>13 kg to 21 kg: 1 mg when first loose stool followed by 1 mg per dose after each subsequent&#x000a0;unformed stool, but not more than 3 mg daily.</p>
          </list-item>
          <list-item>
            <p>21 kg to 27 kg: &#x000a0;2 mg when first loose stool followed by 1 mg per dose after each subsequent unformed stool, but not more than 4 mg daily.</p>
          </list-item>
          <list-item>
            <p>27.1 kg to 43 kg: 2 mg when first loose stool followed by 1 mg per dose after each subsequent&#x000a0;unformed stool, but not more than 6 mg daily.</p>
          </list-item>
          <list-item>
            <p>Children 12 years and older: 4 mg when first loose stool, followed by 2 mg per dose after each subsequent&#x000a0;unformed stool, but not more than 8 mg daily.</p>
          </list-item>
        </list>
        <p><bold>Older patients:&#x000a0;</bold>Use with caution in&#x000a0;older patients due to the risk of paralytic ileus.<xref ref-type="bibr" rid="article-24418.r20">[20]</xref></p>
      </sec>
      <sec id="article-24418.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dry mouth</p>
          </list-item>
          <list-item>
            <p>Flatulence</p>
          </list-item>
          <list-item>
            <p>Abdominal cramps</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Ileus</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Drowsiness&#x000a0;<xref ref-type="bibr" rid="article-24418.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Serious Adverse Drug Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Toxic megacolon</p>
          </list-item>
          <list-item>
            <p>Necrotizing enterocolitis</p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis&#x000a0;<xref ref-type="bibr" rid="article-24418.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>QT/QTc interval prolongation, torsades de pointes, ventricular tachycardia (VT)&#x000a0;<xref ref-type="bibr" rid="article-24418.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>VT storm:&#x000a0;3 or more episodes of VT within 24 hours&#x000a0;<xref ref-type="bibr" rid="article-24418.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Other ventricular arrhythmias and cardiac arrest&#x000a0;<xref ref-type="bibr" rid="article-24418.r23">[23]</xref><bold/></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Loperamide&#x000a0;is extracted in the liver and metabolized&#x000a0;primarily by CYP3A4, a cytochrome P450 enzyme.<xref ref-type="bibr" rid="article-24418.r3">[3]</xref>&#x000a0;The drug is then conjugated and excreted into the bile.&#x000a0;Loperamide has significant drug-drug interactions, and it is essential to check concomitant medicines before prescribing loperamide. Patients with hepatic impairment can have changed first-pass metabolism amounts, leading to CNS adverse reactions. Concomitant administration of lonafarnib may increase the plasma concentration of loperamide. Initially, do not use more than 1 mg of loperamide daily when using loperamide with lonafarnib. If clinically indicated, the dose of loperamide can be cautiously increased.</p>
        <p>Loperamide is a substrate of P-glycoprotein; it can interact with inducers of P-glycoprotein like&#x000a0;carbamazepine, mitotane, phenytoin, and rifampicin. Similarly, loperamide can interact with P-glycoprotein inhibitors like&#x000a0;amiodarone, carvedilol,&#x000a0;ritonavir,&#x000a0;quinidine, itraconazole,&#x000a0;verapamil, clarithromycin, and ranolazine. Use with caution.<xref ref-type="bibr" rid="article-24418.r24">[24]</xref></p>
      </sec>
      <sec id="article-24418.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Loperamide is contraindicated in patients younger than 2 and patients of any age with acute ulcerative colitis, bloody diarrhea, and diarrhea associated with bacterial infections.<xref ref-type="bibr" rid="article-24418.r25">[25]</xref>&#x000a0;Hypersensitivity to loperamide or any excipients is a contraindication to using loperamide.<xref ref-type="bibr" rid="article-24418.r26">[26]</xref>&#x000a0;A case&#x000a0;report&#x000a0;of fatal anaphylaxis has been reported.<xref ref-type="bibr" rid="article-24418.r27">[27]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Loperamide has a boxed warning for torsades de pointes and sudden death when used in higher-than-recommended doses.<xref ref-type="bibr" rid="article-24418.r28">[28]</xref></p>
      </sec>
      <sec id="article-24418.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Currently, loperamide remains available over the counter in pharmacies with restricted access but without a prescription. Patients should&#x000a0;understand the maximum&#x000a0;recommended daily dose when&#x000a0;dispensing loperamide for FDA-approved&#x000a0;or off-label indications. The clinical status of patients and loperamide efficacy should be monitored, in addition to the number of loose stools after each dose. When used in high doses, clinicians should routinely obtain an ECG and assess for signs/symptoms of CNS disturbances and respiratory depression.<xref ref-type="bibr" rid="article-24418.r29">[29]</xref></p>
      </sec>
      <sec id="article-24418.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>When loperamide is taken in large&#x000a0;doses&#x000a0;or&#x000a0;with other drugs that may alter its pharmacokinetic effects, such as p-glycoprotein inhibitors, loperamide produces opioid-like symptoms. These include a sensation of euphoria, miosis, central nervous system depression, and respiratory depression. Treatment of loperamide overdose and toxicity is primarily supportive. Naloxone, including an intranasal naloxone bolus, intravenous naloxone bolus, or naloxone infusion, may be used in patients with respiratory depression.<xref ref-type="bibr" rid="article-24418.r30">[30]</xref>&#x000a0;As naloxone has a shorter half-life than loperamide, patients should be observed for at least 24 hours after the last naloxone administration to ensure they do not deteriorate clinically.</p>
        <p>In large quantities, loperamide can cause systemic effects similar to opioid toxicity (central nervous system depression, respiratory depression) and lethal cardiac conduction abnormalities.<xref ref-type="bibr" rid="article-24418.r3">[3]</xref>&#x000a0;The patient should be on a cardiac monitor, and an&#x000a0;ECG&#x000a0;should be obtained. If QRS widening is present, sodium bicarbonate may be given and repeated in boluses or as an infusion.<xref ref-type="bibr" rid="article-24418.r31">[31]</xref>&#x000a0;</p>
        <p>If the&#x000a0;patient exhibits signs of QTc prolongation (QTc&#x000a0;is considered&#x000a0;prolonged&#x000a0;if greater than 450 ms in males and 470 ms in females), electrolyte abnormalities (magnesium, potassium, phosphate) should be corrected, and isoproterenol or transcutaneous pacing may be an option.<xref ref-type="bibr" rid="article-24418.r32">[32]</xref>&#x000a0;Cardiac arrest is manageable using standard ACLS protocols.</p>
      </sec>
      <sec id="article-24418.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare providers widely prescribe loperamide for different types of diarrhea. Even though&#x000a0;loperamide is available as an over-the-counter medication, its use still requires the attention and oversight of an interprofessional healthcare team. Pharmacists and clinicians&#x000a0;should&#x000a0;check the potential for abuse and educate the patient about its potential toxicity in&#x000a0;higher than recommended&#x000a0;doses. Nurses can also provide monitoring and counseling in this area.</p>
        <p>In September 2019, the FDA approved new package size limitations and unit-dose packaging for certain over-the-counter loperamide products to improve patient safety. When prescribing or recommending loperamide, the nurse and pharmacist should reiterate all safety and dosing issues to ensure proper medication use and optimize patient safety, as patients may think loperamide has no&#x000a0;potential for misuse due to its OTC availability.</p>
        <p>In an overdose, an emergency medicine clinician should rapidly stabilize the patient. A toxicologist consult is necessary for a complicated overdose.&#x000a0;An interprofessional team approach and open communication between&#x000a0;physicians, advanced practice practitioners, nurses, pharmacists, toxicologists, and specialists can&#x000a0;achieve optimal patient&#x000a0;outcomes with fewer adverse effects.</p>
      </sec>
      <sec id="article-24418.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24418&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24418">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24418/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24418">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24418.s11">
        <title>References</title>
        <ref id="article-24418.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Prior</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McKonly</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>DuPont</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Temple</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>A multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children.</article-title>
            <source>Clin Pediatr (Phila)</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>579</fpage>
            <page-range>579-91</page-range>
            <pub-id pub-id-type="pmid">10544864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacDonald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heiner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Villarreal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Strote</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Loperamide dependence and abuse.</article-title>
            <source>BMJ Case Rep</source>
            <year>2015</year>
            <month>May</month>
            <day>02</day>
            <volume>2015</volume>
            <pub-id pub-id-type="pmid">25935922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Clinical Review: Loperamide Toxicity.</article-title>
            <source>Ann Emerg Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-252</page-range>
            <pub-id pub-id-type="pmid">28506439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regnard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Twycross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mihalyo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilcock</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Loperamide.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>319</fpage>
            <page-range>319-23</page-range>
            <pub-id pub-id-type="pmid">21703817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lembo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heidelbaugh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smalley</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Verne</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.</article-title>
            <source>Gastroenterology</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>163</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-151</page-range>
            <pub-id pub-id-type="pmid">35738725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anadkat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brassil</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Caterino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fecher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaiyesimi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Naing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Reichner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Seigel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Spira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swami</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vikas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Funchain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bollin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2021</year>
            <month>Dec</month>
            <day>20</day>
            <volume>39</volume>
            <issue>36</issue>
            <fpage>4073</fpage>
            <page-range>4073-4126</page-range>
            <pub-id pub-id-type="pmid">34724392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vakkalanka</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Holstege</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Epidemiologic Trends in Loperamide Abuse&#x000a0;and&#x000a0;Misuse.</article-title>
            <source>Ann Emerg Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-78</page-range>
            <pub-id pub-id-type="pmid">27823872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litovitz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Korberly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Temple</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>KV</given-names>
              </name>
            </person-group>
            <article-title>Surveillance of loperamide ingestions: an analysis of 216 poison center reports.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1997</year>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-9</page-range>
            <pub-id pub-id-type="pmid">9022646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Killinger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1979</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>211</fpage>
            <page-range>211-8</page-range>
            <pub-id pub-id-type="pmid">438356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandenbossche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huisman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sanderson-Bongiovanni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soons</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance.</article-title>
            <source>J Pharm Pharmacol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>401</fpage>
            <page-range>401-12</page-range>
            <pub-id pub-id-type="pmid">20604828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rampe</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.</article-title>
            <source>Naunyn Schmiedebergs Arch Pharmacol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>389</volume>
            <issue>10</issue>
            <fpage>1133</fpage>
            <page-range>1133-7</page-range>
            <pub-id pub-id-type="pmid">27530870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea.</article-title>
            <source>Drugs</source>
            <year>1978</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-52</page-range>
            <pub-id pub-id-type="pmid">342229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Ericsson</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Kozarsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>DuPont</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Bia</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>ET</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>The practice of travel medicine: guidelines by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <day>15</day>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1499</fpage>
            <page-range>1499-539</page-range>
            <pub-id pub-id-type="pmid">17109284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakken</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Coffin</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shaklee Sammons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <day>19</day>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>e1</fpage>
            <page-range>e1-e48</page-range>
            <pub-id pub-id-type="pmid">29462280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreyev</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Donnellan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lennan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wedlake</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glynne-Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allum</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Guidance on the management of diarrhoea during cancer chemotherapy.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e447</fpage>
            <page-range>e447-60</page-range>
            <pub-id pub-id-type="pmid">25186048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einarson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mastroiacovo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arnon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ornoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Addis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malm</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prospective, controlled, multicentre study of loperamide in pregnancy.</article-title>
            <source>Can J Gastroenterol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-7</page-range>
            <pub-id pub-id-type="pmid">10758415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wald</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Constipation, diarrhea, and symptomatic hemorrhoids during pregnancy.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>309</fpage>
            <page-range>309-22, vii</page-range>
            <pub-id pub-id-type="pmid">12635420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikodem</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Hofmeyr</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Secretion of the antidiarrhoeal agent loperamide oxide in breast milk.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1992</year>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>695</fpage>
            <page-range>695-6</page-range>
            <pub-id pub-id-type="pmid">1623917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shane</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Crump</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tarr</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wanke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Cantey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Nov</month>
            <day>29</day>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>e45</fpage>
            <page-range>e45-e80</page-range>
            <pub-id pub-id-type="pmid">29053792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaniello</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Phillips-Caesar</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Over-the-counter medication overuse and bowel obstruction.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>400</fpage>
            <page-range>400-2</page-range>
            <pub-id pub-id-type="pmid">24521380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teigeler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stahura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alimohammad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kalahasty</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koneru</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ellenbogen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ellenbogen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Electrocardiographic changes in loperamide toxicity: Case report and review of literature.</article-title>
            <source>J Cardiovasc Electrophysiol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>2618</fpage>
            <page-range>2618-2626</page-range>
            <pub-id pub-id-type="pmid">31432581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giesing</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Koester</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Al-Akchar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Labedi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Loperamide-Induced Ventricular Tachycardia Storm.</article-title>
            <source>Avicenna J Med</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-96</page-range>
            <pub-id pub-id-type="pmid">35833161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spinner</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Lonardo</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Mulamalla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stehlik</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ventricular tachycardia associated with high-dose chronic loperamide use.</article-title>
            <source>Pharmacotherapy</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>234</fpage>
            <page-range>234-8</page-range>
            <pub-id pub-id-type="pmid">25645123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asiimwe</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug-Drug-Gene Interactions in Cardiovascular Medicine.</article-title>
            <source>Pharmgenomics Pers Med</source>
            <year>2022</year>
            <volume>15</volume>
            <fpage>879</fpage>
            <page-range>879-911</page-range>
            <pub-id pub-id-type="pmid">36353710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis.</article-title>
            <source>PLoS Med</source>
            <year>2007</year>
            <month>Mar</month>
            <day>27</day>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>e98</fpage>
            <pub-id pub-id-type="pmid">17388664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alary</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chiriac</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Philibert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Demoly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hillaire-Buys</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Delayed hypersensitivity reaction to loperamide: An intriguing case report with positive challenge test.</article-title>
            <source>Allergol Int</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-140</page-range>
            <pub-id pub-id-type="pmid">27363731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srinivasa</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Phelan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Death due to anaphylactic shock after ingestion of Imodium instants (Loperamide).</article-title>
            <source>Allergy</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>965</fpage>
            <page-range>965-6</page-range>
            <pub-id pub-id-type="pmid">17620078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapaganti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anwar Ansari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elkhouly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassib</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Loperamide-Induced Cardiac Arrest.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Jul</month>
            <day>26</day>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e9396</fpage>
            <pub-id pub-id-type="pmid">32864227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggleston</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Marraffa</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Loperamide Abuse Associated With Cardiac Dysrhythmia&#x000a0;and&#x000a0;Death.</article-title>
            <source>Ann Emerg Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-86</page-range>
            <pub-id pub-id-type="pmid">27140747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggleston</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Thornton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stolbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calello</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Marraffa</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Loperamide toxicity: recommendations for patient monitoring and management.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>May</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>355</fpage>
            <page-range>355-359</page-range>
            <pub-id pub-id-type="pmid">31684751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lasoff</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Schneir</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ventricular Dysrhythmias from Loperamide Misuse.</article-title>
            <source>J Emerg Med</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>508</fpage>
            <page-range>508-9</page-range>
            <pub-id pub-id-type="pmid">26794455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24418.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Amaducci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Enyart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burket</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Loperamide-Induced Torsades de Pointes: A Case Series.</article-title>
            <source>J Emerg Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>339</fpage>
            <page-range>339-344</page-range>
            <pub-id pub-id-type="pmid">28755998</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
